Fusion Antibodies plc (AIM: FAB), a specialist in pre-clinical antibody discovery, engineering and supply, announced on Wednesday that it has secured a Canadian patent for its OptiMAL antibody library technology. The Canadian Intellectual Property Office granted patent application CA 3115150, covering two antibody families and methods for designing the libraries.

The patent is expected to support Fusion Antibodies' Opti-designed antibody libraries for antibody discovery, affinity maturation and sequence optimisation. The company continues to progress related patent applications in Europe, China and other territories.

Fusion Antibodies is a Belfast-based contract research organisation providing antibody generation, development, production, characterisation and optimisation services for therapeutic and diagnostic applications.